Jefferies Maintains Buy on Denali Therapeutics, Raises Price Target to $45
Denali Therapeutics +0.67% Pre
Denali Therapeutics DNLI | 20.92 20.92 | +0.67% 0.00% Pre |
Jefferies analyst Michael Yee maintains Denali Therapeutics (NASDAQ:
DNLI) with a Buy and raises the price target from $40 to $45.
